Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Maternal to Infant HIV Transmission in India

X
Trial Profile

Prevention of Maternal to Infant HIV Transmission in India

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nevirapine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWEN
  • Most Recent Events

    • 07 Mar 2018 Results (n=107) determining the association of various markers of inflammation with preterm birth in HIV-infected pregnant women presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 08 Mar 2012 Efficacy analysis according to birth weight presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 16 Feb 2010 Combined analysis of the three SWEN trials presented at the 17th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top